ATE263778T1 - Niedrigallergene proteinvarianten - Google Patents

Niedrigallergene proteinvarianten

Info

Publication number
ATE263778T1
ATE263778T1 AT99947260T AT99947260T ATE263778T1 AT E263778 T1 ATE263778 T1 AT E263778T1 AT 99947260 T AT99947260 T AT 99947260T AT 99947260 T AT99947260 T AT 99947260T AT E263778 T1 ATE263778 T1 AT E263778T1
Authority
AT
Austria
Prior art keywords
protein
parent protein
immunogenicity
low
parent
Prior art date
Application number
AT99947260T
Other languages
English (en)
Inventor
Erwin Ludo Roggen
Arne Agerlin Olsen
Steffen Ernst
Original Assignee
Novozymes As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27221271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE263778(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novozymes As filed Critical Novozymes As
Application granted granted Critical
Publication of ATE263778T1 publication Critical patent/ATE263778T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0061—Laccase (1.10.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
    • C12Y110/03—Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
    • C12Y110/03002—Laccase (1.10.3.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99947260T 1998-10-30 1999-10-12 Niedrigallergene proteinvarianten ATE263778T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA199801402 1998-10-30
DKPA199801645 1998-11-25
DKPA199901417 1999-10-04
PCT/DK1999/000541 WO2000026230A1 (en) 1998-10-30 1999-10-12 Low allergenic protein variants

Publications (1)

Publication Number Publication Date
ATE263778T1 true ATE263778T1 (de) 2004-04-15

Family

ID=27221271

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02020745T ATE390441T1 (de) 1998-10-30 1999-10-12 Niedrigallergene proteinvarianten
AT99947260T ATE263778T1 (de) 1998-10-30 1999-10-12 Niedrigallergene proteinvarianten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02020745T ATE390441T1 (de) 1998-10-30 1999-10-12 Niedrigallergene proteinvarianten

Country Status (10)

Country Link
EP (2) EP1277762B1 (de)
JP (1) JP2003500003A (de)
CN (1) CN1206237C (de)
AT (2) ATE390441T1 (de)
AU (1) AU776534B2 (de)
CA (1) CA2348938A1 (de)
DE (2) DE69938435D1 (de)
ES (1) ES2220114T3 (de)
NZ (1) NZ511291A (de)
WO (1) WO2000026230A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AU2003203147B2 (en) 1998-03-23 2008-05-29 Novozymes A/S Phytase variants
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
AU5805500A (en) * 1999-07-07 2001-01-30 Maxygen Aps A method for preparing modified polypeptides
CA2394377A1 (en) * 1999-12-09 2001-05-10 Novozymes A/S High throughput screening (hts) assays for protein variants with reducedantibody binding capacity
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
AU2001254622A1 (en) * 2000-04-28 2001-11-12 Novozymes A/S Laccase mutants
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
WO2001098484A1 (en) * 2000-06-21 2001-12-27 Novozymes A/S Method for genome mining for secreted protein genes
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
ATE403152T1 (de) * 2000-10-17 2008-08-15 Besst Test Aps Test zum direkten nachweisen einer biologischen zelle in einer körperflüssigkeitsprobe
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
WO2003031981A2 (en) * 2001-10-05 2003-04-17 Novozymes A/S Kit for predicting binding of a specific antibody to a potential immunogen and method of screening
SI1499719T1 (sl) 2002-04-30 2011-03-31 Bayer Healthcare Llc Polipeptidne variante faktorja VII ali VIIa
WO2003096869A2 (en) * 2002-05-16 2003-11-27 Alk Abelló A/S Recombinant bet. v. 1. allergen mutants, methods and process thereof
WO2004031378A2 (en) 2002-10-01 2004-04-15 Novozymes A/S Family gh 61 polypeptides
JP2006513709A (ja) * 2003-02-26 2006-04-27 ジェネンコー・インターナショナル・インク 修飾されたアミラーゼ免疫反応を示すアミラーゼ変異体、及び、これらの製造方法並びに用途
EP2500423B1 (de) * 2003-02-26 2015-06-17 Danisco US Inc. Amylasen, die eine veränderte immunogene Reaktion bewirken, und Verfahren zu ihrer Herstellung und Verwendung
WO2004083361A2 (en) 2003-03-20 2004-09-30 Maxygen Holdings Ltd. FVII OR FVIIa VARIANTS
US7727756B2 (en) 2003-03-21 2010-06-01 Novozymes A/S Subtilases
CN1791672A (zh) * 2003-03-21 2006-06-21 诺和酶股份有限公司 使用基于jp170三维结构的蛋白质建模修饰枯草杆菌酶
CA2529828C (en) 2003-06-19 2013-01-15 Maxygen Holdings Ltd. Factor vii or viia gla domain variants
DE602004027376D1 (de) 2003-06-19 2010-07-08 Novozymes As Proteasen
EP1639107B1 (de) 2003-06-19 2013-08-14 Novozymes A/S Verbesserte proteasen und methoden zu deren herstellung
DE602004030595D1 (de) 2003-10-10 2011-01-27 Novozymes As Proteasevarianten
EP1709165B1 (de) 2004-01-06 2014-04-23 Novozymes A/S Polypeptide von alicyclobacillus
EP1735433B1 (de) 2004-04-02 2010-12-08 Novozymes A/S Subtilasevarianten mit veränderter immunogenität
WO2005123911A2 (en) 2004-06-21 2005-12-29 Novozymes A/S Proteases
AR050895A1 (es) 2004-10-04 2006-11-29 Novozymes As Polipeptidos que tienen actividad de fitasa y polinucleotidos que los codifican
EP1809747B1 (de) 2004-10-04 2016-12-14 Novozymes A/S Polypeptide mit phytaseaktivität und dafür codierende polynukleotide
EP1920052A2 (de) 2005-08-16 2008-05-14 Novozymes A/S Polypeptide des stamms bacillus sp. p203
WO2007107573A1 (en) 2006-03-22 2007-09-27 Novozymes A/S Use of polypeptides having antimicrobial activity
EP2001999B1 (de) 2006-04-04 2012-05-16 Novozymes A/S Phytasevarianten
CN105112386A (zh) 2006-12-21 2015-12-02 诺维信公司 用于药物用途的脂肪酶变体
US8221743B2 (en) 2006-12-22 2012-07-17 Novozymes A/S Use of polypeptides against diseases caused by protozoans
MX289945B (es) 2007-03-26 2011-09-05 Novozymes As Fitasa de hafnia.
JP5056193B2 (ja) * 2007-06-21 2012-10-24 味の素株式会社 畜肉加工食品又は水産加工食品の製造方法及び畜肉加工食品又は水産加工食品改質用の酵素製剤
BRPI0919314A2 (pt) 2008-09-26 2015-08-11 Novozymes As Fitase, métodos para produzir um variante de fitase e um produto de fermentacao, para melhorar o valor nutricional de uma ração animal, e para o tratamento de proteínas vegetais, sequência isolada de ácidos nucleicos, construto de acido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, microorganismo transgênico, ou produtos, ou elementos destes, composição, processo para reduzir níveis de fitato em extrume de animal, e, uso da fitase.
JP5230397B2 (ja) * 2008-12-18 2013-07-10 独立行政法人科学技術振興機構 抗膜貫通型タンパク質抗体の抗原結合部位を決定する方法
US9526768B2 (en) 2014-11-13 2016-12-27 Jennifer Mai Compositions for the treatment of cancer
CN108690841B (zh) * 2018-02-08 2021-10-01 河南科技学院 一种mPEG-Mal5000修饰β-淀粉酶的方法
KR20230050402A (ko) 2020-08-13 2023-04-14 노보자임스 에이/에스 피타제 변이체 및 이를 암호화하는 폴리뉴클레오티드

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69130113T2 (de) 1990-12-05 1999-05-12 Novo Nordisk As Proteine mit geänderten epitopen und verfahren zur deren herstellung
HUT70461A (en) * 1992-04-01 1995-10-30 Merck Anc Co Inc Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv invention
JP3475221B2 (ja) * 1994-09-05 2003-12-08 明治乳業株式会社 免疫原性が低下された変異体タンパク質
JPH08289790A (ja) * 1995-01-06 1996-11-05 Leuven Res & Dev Vzw 新規なスタフィロキナーゼ誘導体
EP0948610B1 (de) 1996-11-04 2011-05-25 Novozymes A/S Subtilase-varianten und verbindungen
US6117642A (en) 1996-11-08 2000-09-12 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods of determining disease activity in SLE patients by correlating the level of soluble CD40 ligand
WO1999038978A1 (en) * 1998-01-31 1999-08-05 University Of Arkansas Methods and reagents for decreasing allergic reactions

Also Published As

Publication number Publication date
NZ511291A (en) 2003-08-29
DE69916306T2 (de) 2005-05-04
AU776534B2 (en) 2004-09-16
EP1277762A3 (de) 2003-04-09
WO2000026230A8 (en) 2000-07-20
EP1124843A1 (de) 2001-08-22
EP1124843B1 (de) 2004-04-07
ATE390441T1 (de) 2008-04-15
AU6078799A (en) 2000-05-22
EP1277762B1 (de) 2008-03-26
CA2348938A1 (en) 2000-05-11
ES2220114T3 (es) 2004-12-01
DE69938435D1 (de) 2008-05-08
JP2003500003A (ja) 2003-01-07
CN1325404A (zh) 2001-12-05
EP1277762A2 (de) 2003-01-22
WO2000026230A1 (en) 2000-05-11
DE69916306D1 (de) 2004-05-13
CN1206237C (zh) 2005-06-15

Similar Documents

Publication Publication Date Title
ATE390441T1 (de) Niedrigallergene proteinvarianten
DE60322188D1 (de) Zytokin (zcytor17-ligand)
HK1078093A1 (en) Antibodies against fibroblast growth factor 23
DK1144607T3 (da) Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
WO2002103024A3 (en) Stabilized proteins with engineered disulfide bonds
IT1227907B (it) Procedimento per la sintesi di peptidi retro-inversi e nuovi intermediin tale procedimento
ATE446104T1 (de) Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor
DK1114156T3 (da) Transformerende vækstfaktor Beta-9 (ZTGFSS9) fra pattedyr
DK1501936T3 (da) Familie af cytokin-proteiner
DK1908772T3 (da) Polypeptider og polynucleinsyrer af phorphorymonas gingivalis
CA2137280A1 (fr) Clonage du gene codant pour la proteine gp28.5 de toxoplasma gondii; fragments peptidiques de cette proteine et leurs applications
DE69929454D1 (de) Neue aminosäuresequenzen, deren kodierende dns, antikörper dagegen und deren verwendungen
CA2441187A1 (en) Acetyllysine-recognizing monoclonal antibody and process for producing the same
AU7655994A (en) Cloning of a member of the serine-threonine-kinase family
DK0779297T3 (da) Antigene peptider med glycinsubstitutioner
DE60124299D1 (de) Peptide aus dem b-glycoprotein des menschlichen herpesvirus-7, besonders anwendbar bei serologischen elisa-nachweisen
WO1994025594A3 (en) Cloning, expression and vaccine composition corresponding to a peptide antigen of toxoplasma gondii
AU2001277717A1 (en) Novel proteins and dnas thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1124843

Country of ref document: EP

REN Ceased due to non-payment of the annual fee